UBS upgraded Novo Nordisk to Neutral from Sell with a price target of DKK 795, up from DKK 360, after assuming coverage of the name. The company’s sector-leading growth is reflected in its “demanding valuation and high market expectations,” the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/15/2024
- Regeneron to test Wegovy drug combos to protect muscle mass, Bloomberg says
- Novo Nordisk price target raised to DKK 850 from DKK 775 at Deutsche Bank
- Novo Nordisk reports COMBINE 3 phase 3a trial achieved primary endpoint
- Tiziana Life files new patent application related to GLP-1ra, foralumab